Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Inhibikase Therapeutics, Inc. Common Stock

IKT

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Last trade $1.40
Day change -$0.055 (-3.79%)
Day range $1.40 – $1.54
Volume 432,035
Market cap $203M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$203.39M
Price / earnings
—
Price / book
1.08×
Price / sales
—
EV / sales
—
EV / EBITDA
-2.03×

Profitability

Earnings per share
-$0.49
Return on assets
-34.29%
Return on equity
-36.64%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
15.34×
Quick ratio
15.34×
Cash ratio
3.99×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$49.37M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for IKT, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$7.23M$7.66M$7.38M$6.77M$5.61M$5.92M$5.25M$5.74M
Research and development$15M$13.39M$10.84M$6.36M$7.65M$5.27M$10.51M$7.19M
Total operating expenses$22.23M$21.05M$17.84M$13.78M$12.77M$10.83M$14.6M$12.93M
Operating income-$22.23M-$21.05M-$17.84M-$13.78M-$12.77M-$10.83M-$14.6M-$12.93M
Interest expense$0$0$0-$2.67M$0$0$0-$273.06K
Income before taxes-$20.47M-$19.59M-$16.38M-$12.73M-$11.93M-$9.92M-$13.68M-$12.13M
Income taxes$0$0$0$0$0$0$0$0
Net income-$20.47M-$19.59M-$16.38M-$12.73M-$11.93M-$9.92M-$13.68M-$12.13M
Net income attributable to common shareholders-$20.47M-$19.59M-$16.38M-$12.73M-$11.93M-$9.92M-$13.68M-$12.13M
EBITDA-$22.23M-$21.05M-$17.84M-$13.78M-$12.74M-$10.81M-$14.59M-$12.92M
Basic earnings per share-$0.10-$0.11-$0.10-$0.10-$0.13-$0.11-$0.15-$0.17
Diluted earnings per share-$0.10-$0.11-$0.10-$0.10-$0.13-$0.11-$0.15-$0.17

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Over 50 pharmaceutical companies are advancing 55+ pipeline drugs for pulmonary arterial hypertension (PAH) treatment. Recent developments include United Therapeutics' ralinepag meeting Phase III endpoints with 55% risk reduction, Gossamer Bio's seralutinib Phase III results, GSK's acquisition of 35Pharma for HS235, and Inhibikase Therapeutics enrolling patients in Phase III IMPROVE-PAH trial. Multiple novel mechanisms of action are being explored to address persistent clinical gaps in PAH management.

GlobeNewswire Inc.

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Inhibikase Therapeutics announced the grant of non-qualified stock options to purchase 685,718 shares to five newly-hired non-executive employees under its 2026 Inducement Equity Plan. The options have an exercise price of $1.68 per share with a ten-year term and a standard vesting schedule of 25% after one year followed by 36 monthly installments.

GlobeNewswire Inc.

BIK-Datenanalyse zeigt: Die Aufnahme von BNPL-Transaktionsdaten in die Kredithistorie könnte fast jedem zweiten „Thin-file-Kunden“ helfen, seine Kreditwürdigkeit zu verbessern

A Polish credit bureau analysis reveals that including Buy Now Pay Later (BNPL) transaction data in credit histories could help nearly 40% of 'thin-file' bank customers improve their creditworthiness, with BNPL transactions showing high repayment rates and low default risks.

Investing.com

Top 10 Small-Cap Stocks to Watch in 2025

The article discusses 10 small-cap stocks that could outperform in 2025, citing factors like falling interest rates, low valuations, and potential shifts in industrial production.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jun 30, 20231-for-6reverse split